+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
S

Actively Recruiting

Researchers are evaluating whether ataciguat can slow the progression of moderate calcific aortic valve stenosis CAVS in adults aged 50 and older. This study is conducted in two parts Part A focuses on whether ataciguat reduces calcium buildup in the aortic valve over 24 weeks, while Part B examines if the drug slows narrowing of the valve area and improves peak oxygen consumption over 48 weeks. Safety, tolerability, and how the body processes ataciguat are also assessed. Participants receive either ataciguat or a placebo daily for up to 156 weeks. Part A enrolls about 132 participants, and Part B will begin after Part A completes, enrolling around 1144 participants. Part B includes additional evaluation of heart function and ability to exercise. The study uses a randomized, double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants undergo imaging tests like CT scans and echocardiograms to measure valve calcium and valve area. Cardiopulmonary exercise testing CPET is used to assess peak oxygen consumption. Researchers also monitor heart function, symptoms, and quality of life using questionnaires. Assessments occur mainly at baseline, Week 24, and Week 48, with long-term follow-up to 156 weeks for safety and efficacy. The studys total duration extends to 2030.

Age: 50Years +All GendersPhase 2Phase 3
74 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
T

Actively Recruiting

Researchers are evaluating a text-based smoking cessation program for rural cancer survivors who smoke. This phase III trial compares an eight-week scheduled gradual reduction program paired with supportive text messages to a control intervention using an informational booklet. The study aims to assess which method better helps these patients quit smoking, with a focus on improving quality of life. The trial targets adults diagnosed with cancer within the past 10 years who currently smoke at least five cigarettes daily and live in rural areas. Participants are randomly assigned to one of two groups. One group follows a personalized eight-week gradual reduction schedule for smoking, supported by 12 weeks of cessation text messages. The other group receives the National Cancer Institutes Clearing the Air booklet to assist with quitting plans. Both groups are followed for six months after their quit date to evaluate outcomes. During the study, participants complete assessments including biochemical validation of smoking cessation up to six months post-quit date. Quality of life is measured at baseline, 30 days, and six months after quitting. Participants provide urine samples and must have texting capability on a phone to receive intervention messages. Safety and progress are monitored throughout, with the total participation lasting up to six months post-quit date.

Age: 18Years +All GendersPhase 3
224 locations
P

Actively Recruiting

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Age: 18Years +All GendersPhase 3
963 locations
S

Actively Recruiting

Chemotherapy-induced peripheral neuropathy CIPN is a side effect caused by chemotherapy drugs that affect the nerves in the hands and feet. This trial evaluates the use of the Lilac Glove and Boot devices, which apply gentle pressure to the hands and feet to reduce chemotherapy exposure to peripheral nerves. The study aims to assess the safety and potential prevention of moderate to severe neuropathy symptoms during cancer treatment. Participants are randomly assigned to either use the Lilac Device or a sham device that looks similar but applies less compression. The devices are fitted and turned on before chemotherapy infusion, worn continuously during infusion, and for up to two hours afterwards. The study focuses on patients receiving specific chemotherapy regimens based on Oxaliplatin or Paclitaxel, with or without additional targeted therapies. During the trial, participants wear the devices during chemotherapy cycles planned for up to 12 months and complete questionnaires related to neuropathy symptoms. Researchers monitor the occurrence of neuropathy symptoms at 12 weeks post-treatment, focusing on overall symptoms and those in the hands. The study also tracks safety and tolerability, with the total participation lasting through the chemotherapy period and follow-up assessments.

Age: 18Years +All GendersPhase Not Applicable
18 locations
S

Actively Recruiting

Researchers are evaluating the Lily Device to see if it can reduce hair loss caused by chemotherapy in adults with breast cancer stages 1 to 3. The study also aims to assess the safety of the device by monitoring any adverse events related to its use. The main questions focus on whether patients preserve their hair after four chemotherapy cycles and the occurrence of any device-related side effects. Participants will use the Lily Device during each chemotherapy session. The device must be worn during the chemotherapy infusion and for at least two hours, up to four hours, after the infusion ends. The study includes at least four cycles of chemotherapy, with various chemotherapy regimens allowed. The devices use is monitored throughout the chemotherapy treatment period. Study participants will be assessed after four chemotherapy cycles for hair preservation by both healthcare professionals and patients themselves. Researchers will collect photographs of the scalp, ask participants to complete quality of life questionnaires, and track how well participants follow the device wear schedule. Safety is closely monitored from enrollment until 30 days after the last treatment, looking for any adverse device events or serious side effects.

Age: 18Years +All GendersPhase Not Applicable
5 locations
S

Actively Recruiting

Researchers are evaluating the Thor system in adults aged 18 years and older who have new, untreated calcified blockages in leg arteries caused by peripheral artery disease PAD. The study aims to determine whether the Thor system is safe and effective for treating these lesions. Patients experience leg pain due to poor blood flow, and the study will observe how the Thor system works in this setting. All participants will receive treatment using the Thor laser atherectomy system, which targets calcified lesions to improve blood flow. During the procedure, doctors may also use additional devices such as angioplasty balloons, drug-coated balloons, stents, and clot-collecting filters if needed. The procedure includes x-ray imaging, and patients will be monitored closely until discharge or for up to 24 hours after treatment. Participants will have follow-up visits at discharge, 30 days, 6 months, and 12 months after the procedure. These visits include medical history reviews, physical exams of the legs, blood flow tests using arm and leg blood pressure comparisons, ultrasound imaging, and questionnaires about walking ability and quality of life. The study will measure outcomes such as freedom from major adverse events, procedural success, lesion openness, and improvements in walking and health surveys over one year.

Age: 18Years +All GendersPhase Not Applicable
29 locations